Griffin Asset Management Inc. lowered its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 6.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,132 shares of the pharmaceutical company's stock after selling 581 shares during the quarter. Griffin Asset Management Inc.'s holdings in Vertex Pharmaceuticals were worth $3,275,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. YHB Investment Advisors Inc. purchased a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at approximately $339,000. Parsons Capital Management Inc. RI increased its stake in Vertex Pharmaceuticals by 27.6% in the fourth quarter. Parsons Capital Management Inc. RI now owns 7,033 shares of the pharmaceutical company's stock valued at $2,832,000 after purchasing an additional 1,521 shares during the period. Heirloom Wealth Management boosted its position in shares of Vertex Pharmaceuticals by 6.7% during the 4th quarter. Heirloom Wealth Management now owns 18,793 shares of the pharmaceutical company's stock worth $7,568,000 after purchasing an additional 1,185 shares in the last quarter. Pacer Advisors Inc. lifted its stake in Vertex Pharmaceuticals by 19.6% in the 4th quarter. Pacer Advisors Inc. now owns 38,800 shares of the pharmaceutical company's stock valued at $15,625,000 after buying an additional 6,359 shares in the last quarter. Finally, United Asset Strategies Inc. grew its holdings in Vertex Pharmaceuticals by 5.2% in the 4th quarter. United Asset Strategies Inc. now owns 3,951 shares of the pharmaceutical company's stock valued at $1,591,000 after buying an additional 196 shares during the period. Hedge funds and other institutional investors own 90.96% of the company's stock.
Vertex Pharmaceuticals Stock Performance
VRTX stock traded down $3.20 during mid-day trading on Tuesday, reaching $440.68. The company had a trading volume of 1,159,523 shares, compared to its average volume of 1,522,945. The stock's 50-day simple moving average is $434.90 and its two-hundred day simple moving average is $463.98. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The stock has a market capitalization of $113.49 billion, a P/E ratio of -221.45, a P/E/G ratio of 2.20 and a beta of 0.40. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating analysts' consensus estimates of $3.61 by $0.77. The firm had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm's revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the firm posted $3.67 earnings per share. Research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current year.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on VRTX. UBS Group raised their price objective on shares of Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a "buy" rating in a report on Tuesday, November 5th. Citigroup started coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, November 14th. They issued a "buy" rating and a $575.00 price objective for the company. Piper Sandler reduced their price objective on Vertex Pharmaceuticals from $535.00 to $533.00 and set an "overweight" rating for the company in a research report on Monday. BMO Capital Markets lowered their price target on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an "outperform" rating for the company in a report on Friday, December 20th. Finally, Raymond James restated a "market perform" rating on shares of Vertex Pharmaceuticals in a report on Thursday, October 10th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $494.76.
View Our Latest Stock Analysis on Vertex Pharmaceuticals
Vertex Pharmaceuticals Company Profile
(
Free Report)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Further Reading
Before you consider Vertex Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.
While Vertex Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
